Lataa...
Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
Imatinib mesylate (IM) is the standard treatment for advanced, metastatic gastrointestinal stromal tumors (GISTs) and chronic myeloid leukemia (CML) with a fixed daily standard dosage via the oral route. Interindividual and intraindividual variability in plasma concentrations have been closely linke...
Tallennettuna:
| Julkaisussa: | Front Pharmacol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7768902/ https://ncbi.nlm.nih.gov/pubmed/33381028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.569843 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|